Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Clinical and Molecular Hepatology. 2022;28(2):269-272 
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
. 2021;
Validation of Fatty Liver Index as a Marker for Metabolic Dysfunction-associated Fatty Liver Disease
. 2021;
Validation of Fatty Liver Index as a Marker for Metabolic Dysfunction-Associated Fatty Liver Disease
. 2021;
Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Diabetes, Metabolic Syndrome and Obesity. 2023;Volume 16:2627-2637
Prevalence of Significant and Advanced Hepatic Fibrosis in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
. 2021;
Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease
Journal of Gastroenterology. 2013;48(5):671-672
A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
Gastro Hep Advances. 2022;1(6):1006-1013
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Diabetology & Metabolic Syndrome. 2022;14(1):
Tu1509 CORRELATION BETWEEN COVID-19 SEVERITY AND NONINVASIVE ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
Gastroenterology. 2023;164(6):S-1394-S-1395